- TM Capital served as exclusive financial advisor to Neoteryx, LLC in connection with its sale to Trajan Group Holdings Limited (Australian Stock Exchange: TRJ)
- Neoteryx, based in Southern California, is a global leader in blood microsampling with operations in the U.S. and Europe
- The Company’s Mitra® devices and proprietary VAMS® technology facilitate more convenient and accurate remote specimen collection, providing better scientific and medical insights
- Headquartered in Melbourne, Australia, Trajan is a global developer and manufacturer of analytical and life sciences products and devices used in the analysis of biological, food, water and other environmental samples
- The transaction further enhances Trajan’s vision to accelerate adoption of remote sampling technologies, expand consumer engagement and facilitate personalized data-based healthcare decisions
Client Testimonial
“At Neoteryx we developed innovative technology to transform specimen collection, and our goal was to achieve global commercial scale through a strategic transaction. TM Capital brought deep industry expertise and relationships to this assignment, and a sharp focus on achieving our objectives. Our partnership with Trajan is an exciting outcome for the Neoteryx team and our customers as we together leverage micro-sampling to create advanced healthcare solutions.”- Fasha Mahjoor, Founder & CEO, Neoteryx, LLC
